Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the NovationBio first quarter 2025 financial results and business update conference call. Please be advised that today's conference call is being recorded. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for questions. I would now like to turn the call over to J.R. DeVita, Executive Director of Corporate Development and Investor Relations at NovationBio. Please go ahead. Thank you, and good afternoon, everyone. Joining me on today's call are Dr. David Hung, our founder, president, and chief executive officer, Colleen Sjogren, our chief commercial officer, and Philippe Sauvage, our chief financial officer. Certain statements we make during this call will be forward-looking. These include statements about talent directives, expected FDA approval, U.S. commercial launch, and potential benefit for patients, our commercial teams launch readiness, and our cash runway. Because such statements deal with future events that are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 10-K and our quarterly reports on Ford 10Q that are filed with the U.S. Securities and Exchange Commission. This afternoon, we released financial results for the quarter ended March 31, 2025, and provided a business update. The press release is available on the investor section of our website at nuvationbio.com. These statements are subject to risks and uncertainties that could cause actual results to differ materially. For more information, please refer to our filings with the SEC. Now, I'll turn the call over to our founder, president, and chie...